Presently, the QPS Respiratory Team is making progress on a large data-intensive, 2-centre allergen challenge study in eosinophilic allergic asthma testing an innovative new drug in close collaboration with our partnering University Centres: Amsterdam (AMC) and Groningen (UMCG). This study is a good example of QPS’ scientific expertise and partnership with academic networks-of-excellence. This enables the team to shape both the preclinical (primary expertise: AMC), clinical/translational (primary expertise: QPS-NL) and genomics (primary expertise: UMCG) trajectories into effective drug development. Upon sponsor’s request, this project has been set up and is being led by Professor Zuzana Diamant, QPS’ Scientific and Medical Director for Respiratory & Allergy, in close collaboration with partners at Amsterdam Medical Centre, Dr Rene Lutter, PhD, Head of Biomarker Lab, and at University Medical Centre Groningen, Associate Professor Maarten van den Berge, Pulmonologist. As part of this project and in close collaboration with the sponsor, the researchers aim to study the molecular-immune-pathophysiologic mechanisms underlying eosinophilic asthma for better understanding of the intervention’s (potential) effects. This exciting project will be part of the Ph.D. thesis of Dr Khalid Abd-Elaziz, QPS co-Primary Investigator, supervised by Zuzana Diamant.
Zuzana Diamant, MD PhD, pulmonologist-clinical pharmacologist, Principal Investigator and Scientific & Executive Medical Director Respiratory & Allergy
Khalid Abd-Elaziz, MD, clinical pharmacologist, Principal Investigator and Safety Officer
Wytze Aalders, MD, Research Physician